Hematologic Cancer

HEMATOLOGIC CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Recommendations From FDA-AACR Workshop to Increase African American Representation in Multiple Myeloma Clinical Trials

A workshop was convened by the US Food and Drug Administration and the American Association for Cancer Research to create recommendations for trial design and later stages of drug development in multiple myeloma.
COVID-19 Vaccination and Imaging Misinterpretation: An Interview With Lacey McIntosh, DO, MPH

Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
Therapeutic Approaches to Multiple Myeloma: An Interview With Ajai Chari, MD

Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma.
American Society of Hematology Releases Updated Guidelines for Treating Newly Diagnosed AML in Older Adults

This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
Data From the CAPTIVATE Study’s uMRD Cohort Suggest Role for Fixed-Duration Therapy in CLL/SLL [Q&A]

John N. Allan, MD, a lead author of the CAPTIVATE study, discusses the findings from the uMRD cohort and their implications for the CLL/SLL paradigm.

HEMATOLOGIC CANCER NEWS

As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.

AlloHCT Following Treatment With PD-1 mAbs Beneficial in Classic Hodgkin Lymphoma

April 9, 2021

blood sample for clinical test

IMiD-Free Regimen Effective in Relapsed/Refractory Multiple Myeloma

April 9, 2021

A blood smear of chronic myeloid leukemia cells.

Dasatinib, Nilotinib Effective Second-Line Therapy for Chronic Myeloid Leukemia

April 8, 2021

Acute Kidney Injury Seen With Induction Chemotherapy for Acute Myeloid Leukemia

April 8, 2021

Increased travel burden is associated with a decreased likelihood of receiving adjuvant chemotherapy

Upfront Low-Dose Chemo-Immunotherapy Safe, Effective for Elderly With CLL

April 7, 2021

Next post in Hematologic Cancers

Leukemia blast cells

Cytogenetics Predict Outcomes to Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia